KR102453227B1 - 항-axl 길항성 항체 - Google Patents

항-axl 길항성 항체 Download PDF

Info

Publication number
KR102453227B1
KR102453227B1 KR1020177018063A KR20177018063A KR102453227B1 KR 102453227 B1 KR102453227 B1 KR 102453227B1 KR 1020177018063 A KR1020177018063 A KR 1020177018063A KR 20177018063 A KR20177018063 A KR 20177018063A KR 102453227 B1 KR102453227 B1 KR 102453227B1
Authority
KR
South Korea
Prior art keywords
antibody
axl
seq
domain
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177018063A
Other languages
English (en)
Korean (ko)
Other versions
KR20170099918A (ko
Inventor
데이비드 로버트 미클렘
세르게이 키프리자노브
제임스 브래들리 로렌스
라비나 아흐메디
린 호드넬란드 닐슨
톤아 산달
Original Assignee
베르젠 테크놀로지오버포링 에이에스
베르겐바이오 에이에스에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베르젠 테크놀로지오버포링 에이에스, 베르겐바이오 에이에스에이 filed Critical 베르젠 테크놀로지오버포링 에이에스
Publication of KR20170099918A publication Critical patent/KR20170099918A/ko
Application granted granted Critical
Publication of KR102453227B1 publication Critical patent/KR102453227B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hospice & Palliative Care (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020177018063A 2014-12-18 2015-12-18 항-axl 길항성 항체 Active KR102453227B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201422605 2014-12-18
GB1422605.4 2014-12-18
PCT/EP2015/080654 WO2016097370A2 (en) 2014-12-18 2015-12-18 Anti-axl antagonistic antibodies

Publications (2)

Publication Number Publication Date
KR20170099918A KR20170099918A (ko) 2017-09-01
KR102453227B1 true KR102453227B1 (ko) 2022-10-11

Family

ID=55080088

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177018063A Active KR102453227B1 (ko) 2014-12-18 2015-12-18 항-axl 길항성 항체

Country Status (9)

Country Link
US (3) US10208121B2 (enExample)
EP (1) EP3233119A2 (enExample)
JP (2) JP6931609B2 (enExample)
KR (1) KR102453227B1 (enExample)
CN (2) CN107531786B (enExample)
AU (1) AU2015366213B2 (enExample)
CA (1) CA2969879A1 (enExample)
MX (1) MX390849B (enExample)
WO (1) WO2016097370A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410826D0 (en) 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
GB201410825D0 (en) * 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
EP3233119A2 (en) 2014-12-18 2017-10-25 Bergen Teknologioverforing AS Anti-axl antagonistic antibodies
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201509338D0 (en) 2015-05-29 2015-07-15 Bergenbio As Combination therapy
GB201610902D0 (en) * 2016-06-22 2016-08-03 Bergen Teknologioverforing As And Bergenbio As Anti-Axl Antagonistic Antibodies
CA3070342A1 (en) * 2017-07-18 2019-01-24 Kyowa Kirin Co., Ltd. Anti-human ccr1 monoclonal antibody
EP3774904A1 (en) * 2018-04-10 2021-02-17 Genmab A/S Axl-specific antibodies for cancer treatment
US20210215697A1 (en) 2018-05-14 2021-07-15 Bergenbio Asa Serum Biomarkers
CN110540592B (zh) * 2018-05-29 2022-08-09 杭州尚健生物技术有限公司 结合axl蛋白的抗体及其应用
CN109206489A (zh) * 2018-09-29 2019-01-15 未名生物医药有限公司 蛋白序列12g12及其用途
CN109206490A (zh) * 2018-09-29 2019-01-15 未名生物医药有限公司 蛋白序列11b09及其用途
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
EP3946453A4 (en) * 2019-03-29 2022-12-07 Celldex Therapeutics, Inc. ANTI-AXL ANTIBODIES AND THEIR METHODS OF USE
GB201912059D0 (en) 2019-08-22 2019-10-09 Bergenbio As Combaination therapy of a patient subgroup
WO2021154156A1 (en) * 2020-01-31 2021-08-05 Agency For Science, Technology And Research Anti-axl antibody and uses thereof
BR112022015977A2 (pt) 2020-02-28 2022-10-11 Symphogen As Anticorpos anti-axl e composições
GB202004189D0 (en) 2020-03-23 2020-05-06 Bergenbio As Combination therapy
IL297132A (en) 2020-04-08 2022-12-01 Bergenbio Asa axl inhibitors for antiviral therapy
GB202006072D0 (en) 2020-04-24 2020-06-10 Bergenbio Asa Method of selecting patients for treatment with cmbination therapy
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
MX2023008744A (es) 2021-01-29 2023-10-02 Illimis Therapeutics Inc Molecula de fusion que tiene actividad no inflamatoria inductora de la fagocitosis.
GB202104037D0 (en) 2021-03-23 2021-05-05 Bergenbio Asa Combination therapy
EP4357365A4 (en) * 2021-06-16 2025-06-04 Shanghai Sinobay Biotechnology Co., Ltd. Antibodies against AXL protein and antigen-binding fragment thereof, as well as methods of production and use thereof
CN121263449A (zh) * 2023-03-21 2026-01-02 拜格拉夫55公司 Cd19/cd38多特异性抗体

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1382969A1 (en) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
KR101672664B1 (ko) * 2003-07-21 2016-11-04 이뮤노젠 아이엔씨 인간화된 항체 또는 그의 항원결정기 결합절편
CA2705164A1 (en) * 2007-11-12 2009-05-22 U3 Pharma Gmbh Axl antibodies
KR101568051B1 (ko) * 2007-11-15 2015-11-10 추가이 세이야쿠 가부시키가이샤 Ａｎｅｘｅｌｅｋｔｏ에 결합하는 단일클론항체, 및 그의 이용
JP5909442B2 (ja) 2009-05-11 2016-04-26 ユー３・ファーマ・ゲーエムベーハー ヒト化ａｘｌ抗体
TW201106972A (en) 2009-07-27 2011-03-01 Genentech Inc Combination treatments
CA2794731C (en) 2010-06-18 2019-03-19 Genentech, Inc. Anti-axl antibodies and methods of use
EP2596136B1 (en) 2011-05-06 2014-07-16 Zhongshan Hospital Fudan University Marker consisting of plasma microrna and new method for diagnosis of hepatocellular carcinoma
JP6033293B2 (ja) 2011-06-22 2016-11-30 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル）Ｉｎｓｅｒｍ（Ｉｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ Ｄｅｌａ Ｓａｎｔｅ Ｅｔ Ｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｍｅｄｉｃａｌｅ） 抗Ａｘｌ抗体及びその使用
US9409988B2 (en) 2011-06-22 2016-08-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-Axl antibodies and uses thereof
EP2589609A1 (en) * 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer
US9879061B2 (en) * 2011-12-15 2018-01-30 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
EP2868644B1 (en) 2012-06-29 2018-08-01 Mitsubishi Gas Chemical Company, Inc. Method and apparatus for separating alkyl aromatic hydrocarbon
CA2890265C (en) * 2012-11-05 2023-01-17 Pierre Fabre Medicament Antigen binding proteins and their use as addressing product for the treatment of cancer
GB201410826D0 (en) * 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
GB201410825D0 (en) * 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
US9986723B2 (en) * 2014-10-22 2018-06-05 The Board Of Regents Of The University Of Texas System Screen and use of therapeutics for pancreatic ductal adenocarcinoma
EP3233119A2 (en) * 2014-12-18 2017-10-25 Bergen Teknologioverforing AS Anti-axl antagonistic antibodies
GB201610902D0 (en) * 2016-06-22 2016-08-03 Bergen Teknologioverforing As And Bergenbio As Anti-Axl Antagonistic Antibodies

Also Published As

Publication number Publication date
CN107531786A (zh) 2018-01-02
JP2018506961A (ja) 2018-03-15
AU2015366213A1 (en) 2017-06-22
CN116410318A (zh) 2023-07-11
US20190177419A1 (en) 2019-06-13
JP2021101707A (ja) 2021-07-15
WO2016097370A3 (en) 2016-08-11
CA2969879A1 (en) 2016-06-23
CN107531786B (zh) 2023-01-13
US11584796B2 (en) 2023-02-21
EP3233119A2 (en) 2017-10-25
WO2016097370A2 (en) 2016-06-23
MX2017007941A (es) 2018-01-30
AU2015366213B2 (en) 2021-10-07
JP6931609B2 (ja) 2021-09-08
US20230406941A1 (en) 2023-12-21
US10208121B2 (en) 2019-02-19
KR20170099918A (ko) 2017-09-01
MX390849B (es) 2025-03-21
US20170349658A1 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
US20230406941A1 (en) Anti-AXL Antagonistic Antibodies
US11732048B2 (en) Anti-axl antagonistic antibodies
US11186643B2 (en) Anti-Axl antibodies
KR102408356B1 (ko) 항―axl 항체
HK40057042A (en) Anti-axl antibodies
HK40062721A (en) Anti-axl antibodies
HK40096197A (zh) 抗axl拮抗抗体

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170629

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201217

Comment text: Request for Examination of Application

A302 Request for accelerated examination
AMND Amendment
PA0302 Request for accelerated examination

Patent event date: 20211223

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220420

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220704

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220420

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220704

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20220602

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20211223

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20201217

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20220830

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20220819

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20220704

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20220602

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20211223

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20201217

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20221005

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20221006

End annual number: 3

Start annual number: 1

PG1601 Publication of registration